Karapinar-Çarkit Fatma, van den Bemt Patricia M L A, Sadik Mariam, van Soest Brigit, Knol Wilma, van Hunsel Florence, van Riet-Nales Diana A
Department of Clinical Pharmacy, OLVG hospital, Amsterdam, The Netherlands.
Department of Hospital Pharmacy, University Medical Center Groningen, Groningen, The Netherlands.
Br J Clin Pharmacol. 2020 Oct;86(10):1946-1957. doi: 10.1111/bcp.14392. Epub 2020 Jun 24.
Medication safety requires urgent attention in hospital pharmacy. This study evaluated the medication-related problems/errors as reported to the Dutch medication incident registry and disseminated for information to pharmacists. Through analysis by an expert panel we aimed to better understand which problems could have been mitigated by the drug product design. Additionally, the (wider) implications of the problems for current hospital/clinical practice were discussed.
Items were extracted from the public Portal for Patient Safety. Items were included if relevant for older people and connected with the drug product design and excluded if they should reasonably have been intercepted by compliance to routine controls or well-known professional standards in pharmaceutical care. To explore any underreporting of well-known incidents, it was investigated if different medication-related problems could be observed in a regional hospital practise over a 1-month period. For 6 included items (cases), the implications for hospital/clinical practise were discussed in an expert panel.
In total, 307 items were identified in the Portal for Patient Safety; all but 14 were excluded. Six cases were added from daily hospital practice. These 20 cases commonly related to confusing product characteristics, packaging issues such as the lack of a single unit package for an oncolytic product, or incorrect or incomplete user instructions.
Medication registries provide important opportunities to evaluate real-world medication-related problems. However, underreporting of well-known problems should be considered. The product design can be used as an (additional) risk mitigation measure to support medication safety in hospital practice.
医院药房中的用药安全问题亟待关注。本研究评估了向荷兰用药事件登记处报告并向药剂师发布以供参考的用药相关问题/差错。通过专家小组分析,我们旨在更好地了解哪些问题可通过药品设计得到缓解。此外,还讨论了这些问题对当前医院/临床实践的(更广泛)影响。
从患者安全公共门户网站提取条目。如果条目与老年人相关且与药品设计有关,则予以纳入;如果按照药物治疗中的常规控制或知名专业标准本应合理拦截这些条目,则予以排除。为探究是否存在对知名事件的漏报情况,调查了在一家地区医院1个月的实践中是否能观察到不同的用药相关问题。对于6个纳入条目(案例),专家小组讨论了其对医院/临床实践的影响。
在患者安全门户网站上共识别出307个条目;除14个外均被排除。从日常医院实践中补充了6个案例。这20个案例通常与产品特性混淆、包装问题(如溶瘤产品缺乏单剂量包装)或用户说明不正确或不完整有关。
用药登记为评估实际用药相关问题提供了重要机会。然而,应考虑到知名问题的漏报情况。产品设计可作为一种(额外的)风险缓解措施,以支持医院实践中的用药安全。